Page 102 - 《中国药房》2023年4期
P. 102

·循证药学·


          帕瑞昔布对比酮咯酸氨丁三醇用于围手术期镇痛有效性和安全
          性的系统评价
                                Δ


                *
          林 茂 ,胡志强,陈 娅,肖洪涛,蒋 倩(四川省肿瘤医院研究所/四川省癌症防治中心/电子科技大学医学院
                                                #
          附属肿瘤医院药学部,成都 610041)

          中图分类号  R971      文献标志码  A      文章编号  1001-0408(2023)04-0476-07
          DOI  10.6039/j.issn.1001-0408.2023.04.18

          摘   要  目的  比较帕瑞昔布与酮咯酸氨丁三醇用于围手术期镇痛的有效性和安全性,为临床用药提供循证参考。方法  计算机
          检索 PubMed、Embase、the Cochrane Library、中国知网、维普网、万方数据库和百度、谷歌网站,收集帕瑞昔布(试验组)对比酮咯
          酸氨丁三醇(对照组)的随机对照试验(RCT),检索时限为各数据库建库起至 2022 年 6 月 17 日。筛选文献、提取资料后,采用
          Cochrane系统评价员手册5.1.0推荐的偏倚风险评估工具对纳入文献质量进行评价;采用RevMan 5.4软件进行Meta分析、敏感性
          分析和发表偏倚分析。结果  共纳入12项RCT,合计1 118例患者。Meta分析结果显示,麻醉诱导前给药时,两组患者的视觉模拟
          评分(VAS)[MD=-0.16,95%CI(-0.41,0.09),P=0.20]、疼痛数字评分(NRS)[MD=0.01,95%CI(-0.36,0.38),P=0.97]、术后
          出血量[MD=0.15,95%CI(-0.63,0.93),P=0.71]、术后阿片类镇痛药消耗量[MD=0.12,95%CI(-0.77,1.01),P=0.79]比较,差
          异均无统计学意义。术后给药时,试验组患者的VAS、术后48 h出血量均显著低于或少于对照组(P<0.05)。按不同评估时间进
          行亚组分析的结果显示,麻醉诱导前给药时,试验组患者术后0 h时的VAS显著低于对照组;术后给药时,试验组患者术后12、48 h
          的 VAS 均显著低于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义[RR=0.93,95%CI(0.78,1.11),P=
          0.43]。按不同不良反应类型进行亚组分析的结果显示,试验组患者的恶心呕吐发生率显著低于对照组,其他不良反应发生率显著
          高于对照组(P<0.05)。敏感性分析结果显示,本研究所得结果稳健。发表偏倚分析结果显示,本研究存在发表偏倚的可能性较
          大。结论  帕瑞昔布与酮咯酸氨丁三醇术前用于围手术期镇痛的疗效相当;术后给药时,帕瑞昔布的镇痛效果更好、术后出血量更
          少;无论何时给药,帕瑞昔布的恶心呕吐发生率更低。
          关键词  帕瑞昔布;酮咯酸氨丁三醇;围手术期;镇痛;有效性;安全性

          Efficacy  and  safety  of  parecoxib  versus  ketorolac  tromethamine  for  perioperative  analgesia:  a  systematic
          review
          LIN Mao,HU Zhiqiang,CHEN Ya,XIAO Hongtao,JIANG Qian(Dept.  of  Pharmacy,  Sichuan  Cancer  Hospital  &
          Institute/Sichuan  Cancer  Center/Cancer  Hospital  Affiliated  to  School  of  Medicine,  University  of  Electronic

          Science and Technology of China, Chengdu 610041, China)

          ABSTRACT    OBJECTIVE  To  compare  the  efficacy  and  safety  of  parecoxib  and  ketorolac  tromethamine  for  perioperative
          analgesia,  and  to  provide  evidence-based  reference  for  clinical  drug  use.  METHODS  Retrieved  from  PubMed,  Embase,  the
          Cochrane  Library,  CNKI,  VIP,  Wanfang  Data,  Baidu  and  Google,  randomized  controlled  trials (RCT)  about  parecoxib (trial
          group)  versus  ketorolac  tromethamine (control  group)  for  perioperative  analgesia  were  collected  from  the  inception  to  Jun.  17th,
          2022. After  screening  the  literature  and  extracting  the  data,  the  quality  of  the  included  literature  was  evaluated  using  the  bias  risk
          assessment  tool  recommended  by  Cochrane  system  evaluator  manual  5.1.0.  Meta-analysis,  sensitivity  analysis  and  publication  bias
          analysis  were  performed  with  RevMan  5.4  software.  RESULTS  A  total  of  12  RCTs  were  included,  with  1  118  patients.  Meta-
          analysis results showed that at the time of administration before anesthesia induction, there was no statistically significant difference
          between  the  2  groups  in  visual  analogue  scale (VAS)  [MD=-0.16,  95%CI (-0.41,  0.09),  P=0.20],  numerical  rating  scale
         (NRS)  [MD=0.01,  95%CI (-0.36,  0.38),  P=0.97],  postoperative  bleeding  [MD=0.15,  95%CI (-0.63,  0.93),  P=0.71],
                                                              and  consumption  of  opioid  analgesics  [MD=0.12,  95%CI
              Δ 基金项目 四川省卫生健康委员会医学科技项目(No.21PJ115)
                                                             (-0.77,  1.01),  P=0.79].  At  the  time  of  postoperative
             * 第一作者 药 师 ,硕 士 。 研 究 方 向 :临 床 药 学 。 电 话 :028-
                                                              administration,  VAS  and  bleeding  volume  at  48  h  after
          85420338。E-mail:642800758@qq.com
                                                              operation  of  trial  group  were  significantly  lower  than  control
              # 通信作者 副主任药师,博士。研究方向:循证药物评价方法与
          决策转化。电话:028-85420338。E-mail:jiangqian_3805.student@sina.  group (P<0.05). The results of subgroup analysis by different
          com                                                 assessment time points showed that the VAS of patients in trial


          · 476 ·    China Pharmacy  2023 Vol. 34  No. 4                               中国药房  2023年第34卷第4期
   97   98   99   100   101   102   103   104   105   106   107